WO2018024110A8 - Mg53突变体及其制备方法和用途 - Google Patents

Mg53突变体及其制备方法和用途 Download PDF

Info

Publication number
WO2018024110A8
WO2018024110A8 PCT/CN2017/093640 CN2017093640W WO2018024110A8 WO 2018024110 A8 WO2018024110 A8 WO 2018024110A8 CN 2017093640 W CN2017093640 W CN 2017093640W WO 2018024110 A8 WO2018024110 A8 WO 2018024110A8
Authority
WO
WIPO (PCT)
Prior art keywords
diseases
mutant
diabetes mellitus
preparation
neuropathies
Prior art date
Application number
PCT/CN2017/093640
Other languages
English (en)
French (fr)
Other versions
WO2018024110A1 (zh
Inventor
肖瑞平
吕凤祥
张岩
郭寺乐
Original Assignee
北京大学
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from CN201610847346.4A external-priority patent/CN107868125A/zh
Application filed by 北京大学 filed Critical 北京大学
Priority to CA3031856A priority Critical patent/CA3031856A1/en
Priority to SG11201900459RA priority patent/SG11201900459RA/en
Priority to EP17836292.7A priority patent/EP3492491A4/en
Priority to JP2019505531A priority patent/JP7144402B2/ja
Priority to KR1020197005658A priority patent/KR102483242B1/ko
Priority to CN201780003946.5A priority patent/CN108473546B/zh
Publication of WO2018024110A1 publication Critical patent/WO2018024110A1/zh
Publication of WO2018024110A8 publication Critical patent/WO2018024110A8/zh
Priority to HK18114549.7A priority patent/HK1255559A1/zh
Priority to US16/262,833 priority patent/US11306296B2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1025—Acyltransferases (2.3)
    • C12N9/104—Aminoacyltransferases (2.3.2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y203/00—Acyltransferases (2.3)
    • C12Y203/02—Aminoacyltransferases (2.3.2)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cardiology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Vascular Medicine (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

一种MG53突变体，在野生型MG53的coiled-coil-SPRY区域内具有至少一个丝氨酸缺失和/或突变为任何其他非丝氨酸或苏氨酸的氨基酸。包括所述MG53突变体的药物组合物；编码所述MG53突变体的核酸；所述MG53突变体的制备方法；所述MG53突变体在制备用于治疗心脏疾病、糖尿病脑血管疾病、糖尿病眼部并发症、糖尿病神经病变、糖尿病足、肾脏疾病、与细胞和/或组织损伤相关疾病的药物中的用途，特别地，所述MG53突变体在治疗心脏疾病、糖尿病脑血管疾病、糖尿病眼部并发症、糖尿病神经病变、糖尿病足、肾脏疾病、与细胞和/或组织损伤相关疾病的同时，能够避免或减少野生型MG53所带来的代谢类副作用，例如，胰岛素抵抗、肥胖、糖尿病、高血压、血脂异常等。
PCT/CN2017/093640 2016-08-01 2017-07-20 Mg53突变体及其制备方法和用途 WO2018024110A1 (zh)

Priority Applications (8)

Application Number Priority Date Filing Date Title
CA3031856A CA3031856A1 (en) 2016-08-01 2017-07-20 Mg53 mutants, methods of making the same, and uses thereof
SG11201900459RA SG11201900459RA (en) 2016-08-01 2017-07-20 Mg53 mutants, methods of making the same, and uses thereof
EP17836292.7A EP3492491A4 (en) 2016-08-01 2017-07-20 MUTANT TO MG53, PREPARATION METHOD THEREOF AND USES THEREOF
JP2019505531A JP7144402B2 (ja) 2016-08-01 2017-07-20 Ｍｇ５３突然変異体、その作製方法、およびその使用
KR1020197005658A KR102483242B1 (ko) 2016-08-01 2017-07-20 Mg53 돌연변이체, 및 그의 제조 방법 및 그의 용도
CN201780003946.5A CN108473546B (zh) 2016-08-01 2017-07-20 Mg53突变体及其制备方法和用途
HK18114549.7A HK1255559A1 (zh) 2016-08-01 2018-11-14 Mg53突變體及其製備方法和用途
US16/262,833 US11306296B2 (en) 2016-08-01 2019-01-30 MG53 mutants, methods of making the same, and uses thereof

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
CN201610621989.7 2016-08-01
CN201610621989 2016-08-01
CN201610847346.4 2016-09-23
CN201610847346.4A CN107868125A (zh) 2016-09-23 2016-09-23 Mg53突变体及其制备方法和用途
CN201710560975 2017-07-11
CN201710560975.3 2017-07-11

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US16/262,833 Continuation-In-Part US11306296B2 (en) 2016-08-01 2019-01-30 MG53 mutants, methods of making the same, and uses thereof

Publications (2)

Publication Number Publication Date
WO2018024110A1 WO2018024110A1 (zh) 2018-02-08
WO2018024110A8 true WO2018024110A8 (zh) 2018-11-01

Family

ID=61073266

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2017/093640 WO2018024110A1 (zh) 2016-08-01 2017-07-20 Mg53突变体及其制备方法和用途

Country Status (11)

Country Link
US (1) US11306296B2 (zh)
EP (1) EP3492491A4 (zh)
JP (1) JP7144402B2 (zh)
KR (1) KR102483242B1 (zh)
CN (1) CN108473546B (zh)
CA (1) CA3031856A1 (zh)
HK (1) HK1255559A1 (zh)
MA (1) MA45797A (zh)
SG (1) SG11201900459RA (zh)
TW (1) TWI781948B (zh)
WO (1) WO2018024110A1 (zh)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108478800A (zh) * 2018-04-02 2018-09-04 慎东 含mg53/其突变体的组合物在制备炎症性肠病药物的应用
US20200179482A1 (en) * 2018-12-07 2020-06-11 Ohio State Innovation Foundation Composition for and method of facilitating corneal tissue repair
EP3982999A4 (en) * 2019-06-17 2023-07-19 Trim-Edicine, Inc. COMPOSITION AND METHODS OF TREATMENT OF LIVER TISSUE DAMAGE
CN115379823A (zh) * 2020-01-23 2022-11-22 俄亥俄州立创新基金会 药妆组合物
WO2024002062A1 (en) * 2022-06-28 2024-01-04 Sineugene Therapeutics Co., Ltd. A truncated protein and use thereof
WO2024002059A1 (en) * 2022-06-28 2024-01-04 Sineugene Therapeutics Co., Ltd. Method for treating a parkinson's disease
WO2024002056A1 (en) * 2022-06-28 2024-01-04 Sineugene Therapeutics Co., Ltd. Aav gene therapy for treating a nervous system disease

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6703219B1 (en) 1993-02-26 2004-03-09 Immtech International Inc. Mutant protein and methods and materials for making and using it
JP4734251B2 (ja) 2003-10-07 2011-07-27 ユニバーシティ・オブ・オックスフォード チロシナーゼ突然変異体及びその使用方法
US9139630B2 (en) 2006-07-11 2015-09-22 Rutgers, The State University Of New Jersey Compositions and methods for preparing recombinant MG53 and methods for optimizing same
EP2471809B1 (en) 2006-07-11 2015-09-02 University Of Medicine And Dentistry Of New Jersey Proteins, nucleic acids encoding the same and associated methods of use
EP2215126A4 (en) * 2007-12-04 2011-03-23 Univ New Jersey Med COMPOSITIONS AND METHOD FOR MODULATING THE CELL MEMBRANE RE-SEALING
JOP20190083A1 (ar) 2008-06-04 2017-06-16 Amgen Inc بولي ببتيدات اندماجية طافرة لـfgf21 واستخداماتها
CN101797375B (zh) * 2009-12-02 2013-01-23 北京大学 Mg53蛋白预防和/或治疗心脏缺血/再灌损伤的用途
CN101912617B (zh) * 2010-07-29 2012-09-26 北京大学 Mg53基因在治疗胰岛素抵抗和ⅱ型糖尿病及其相关病症中的应用
US8420338B2 (en) 2010-11-05 2013-04-16 University Of Medicine And Dentistry Of New Jersey Serum MG53 as a diagnostic marker for tissue injury
WO2012134478A1 (en) 2011-03-31 2012-10-04 University Of Medicine And Dentistry Of New Jersey Compositions and methods for the treatment and prevention of cardiac ischemic injury
US20140024594A1 (en) 2011-03-31 2014-01-23 Noah Weisleder Compositions and methods for the treatment and prevention of cardiac ischemic injury
CN104066452A (zh) * 2011-09-07 2014-09-24 新泽西医科和牙科大学 治疗和预防气道损伤的含mg53组合物及方法
CN103965342B (zh) * 2013-01-25 2015-06-10 北京博雅和瑞科技有限公司 一种mg53突变体及其突变方法和应用
CN103966227B (zh) 2014-03-06 2015-05-27 北京博雅和瑞科技有限公司 密码子优化的mg53蛋白的编码核苷酸序列、其重组体及其应用
CN107266551B (zh) * 2016-04-06 2021-03-05 牡丹江友搏药业有限责任公司 一种mg53突变体及其制备方法和应用
CN107987147A (zh) * 2016-10-26 2018-05-04 王惠琴 一种mg53多聚体制备方法及其用途
CN108721601A (zh) 2018-07-26 2018-11-02 海南博芝康医疗科技有限公司 一种预防和/或治疗肾损伤和肾衰竭的组合物
CN109528684A (zh) 2018-12-26 2019-03-29 牡丹江友搏药业有限责任公司 一种mg53蛋白/mg53突变体蛋白肠溶胶囊及其制备方法
CN109432404A (zh) 2018-12-26 2019-03-08 牡丹江友搏药业有限责任公司 一种含mg53蛋白/mg53突变体蛋白凝胶及其制备方法和应用

Also Published As

Publication number Publication date
KR102483242B1 (ko) 2022-12-29
US11306296B2 (en) 2022-04-19
CN108473546B (zh) 2022-08-16
JP2019530433A (ja) 2019-10-24
US20190153406A1 (en) 2019-05-23
MA45797A (fr) 2021-04-21
TW201805299A (zh) 2018-02-16
EP3492491A1 (en) 2019-06-05
CN108473546A (zh) 2018-08-31
SG11201900459RA (en) 2019-02-27
CA3031856A1 (en) 2018-02-08
JP7144402B2 (ja) 2022-09-29
HK1255559A1 (zh) 2019-08-23
EP3492491A4 (en) 2020-02-19
KR20190034278A (ko) 2019-04-01
WO2018024110A1 (zh) 2018-02-08
TWI781948B (zh) 2022-11-01

Similar Documents

Publication Publication Date Title
WO2018024110A8 (zh) Mg53突变体及其制备方法和用途
EP4241784A3 (en) Artificial nucleic acid molecules for improved protein expression
MX2019012081A (es) Proteina de fusion del factor de crecimiento 21 de fibroblastos humanos (hfgf21), metodo de preparacion de la misma y su uso.
WO2016176690A3 (en) Gene therapy for autosomal dominant diseases
WO2017077329A3 (en) Nucleic acids, peptides and methods
EA201792203A1 (ru) Фармацевтические композиции для комбинированной терапии
MX2018005193A (es) Proteinas de doble funcion y composicion farmaceutica que comprende las mismas.
MX336412B (es) Nuevos analogos de glucagon.
EP4309643A3 (en) Viscosity-reducing excipient compounds for protein formulations
WO2013092703A3 (en) Glucagon analogues
JP2016532690A5 (zh)
MX2016002152A (es) Metodo para aumentar la expresion de proteinas codificadas por arn.
TR201900649T4 (tr) Oküler hastalıkların tedavisi için mrna tedavisi.
BR112015003109A2 (pt) Composto, composição, uso de um composto, e, métodos para tratar ou prevenir um distúrbio, condição ou doença e para tratar diabetes mellitus tipo 2.
WO2011072288A3 (en) Insulin analogues with chlorinated amino acids
EA201590759A1 (ru) Композиция для лечения диабета или диажирения, содержащая аналог оксинтомодулина
MY158627A (en) Halogen-stabilized insulin
EA201201657A1 (ru) Лечение диабета
MX2018005387A (es) Variantes de fgf21.
MA40709A1 (fr) Dérivé du glucagon à stabilité améliorée
EA201170551A1 (ru) Способы лечения заболеваний глаз
MX369550B (es) Gen de fusion del receptor de factor de crecimiento de fibroblastos 3 (fgfr3) y medicamentos farmaceutico para tratar el mismo.
MA40057A (fr) Traitement thérapeutique de maladie cutanée au moyen de micro-organismes cutanés commensaux recombinants
NZ703597A (en) Mutant fragments of ospa and methods and uses relating thereto
AU2012366182A8 (en) Method of treating diabetes using non-glycosylated apolipoprotein A-IV

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 17836292

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 3031856

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 2019505531

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 20197005658

Country of ref document: KR

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2017836292

Country of ref document: EP

Effective date: 20190301